<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Family Reprod Health</journal-id><journal-id journal-id-type="iso-abbrev">J Family Reprod Health</journal-id><journal-id journal-id-type="publisher-id">JFRH</journal-id><journal-title-group><journal-title>Journal of Family &#x00026; Reproductive Health</journal-title></journal-title-group><issn pub-type="ppub">1735-8949</issn><issn pub-type="epub">1735-9392</issn><publisher><publisher-name>Vali-e-Asr Reproductive Health Research Center, Tehran University of Medical Sciences</publisher-name><publisher-loc>Tehran, Iran</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25530766</article-id><article-id pub-id-type="pmc">4266785</article-id><article-id pub-id-type="publisher-id">JFRH-8-149</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Luteal Phase Support in the Intrauterine Insemination (IUI) Cycles: A Randomized Double Blind, Placebo Controlled Study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hossein Rashidi</surname><given-names>Batool</given-names></name><degrees>M.D.</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Davari Tanha</surname><given-names>Fatemeh</given-names></name><degrees>M.D.</degrees><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Rahmanpour</surname><given-names>Haleh</given-names></name><degrees>M.D.</degrees><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Ghazizadeh</surname><given-names>Mahya</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Reproductive Health Research Center, Tehran University of Medical Sciences, Tehran, Iran</aff><aff id="aff2"><label>2</label>Zanan Hospital, Tehran University of Medical Sciences, Tehran, Iran</aff><aff id="aff3"><label>3</label>Zanjan University of Medical Sciences, Zanjan, Iran</aff><author-notes><corresp id="cor">Correspondence: Batool Hossein Rashidi, Reproductive Health Research Center, Emam Hospital, Keshavarz blvd., Tehran, Iran<email>bhrashidi@tums.ac.ir</email></corresp></author-notes><pub-date pub-type="ppub"><month>12</month><year>2014</year></pub-date><volume>8</volume><issue>4</issue><fpage>149</fpage><lpage>153</lpage><history><date date-type="received"><month>10</month><year>2014</year></date><date date-type="rev-recd"><month>10</month><year>2014</year></date><date date-type="accepted"><month>10</month><year>2014</year></date></history><permissions><copyright-statement>Copyright &#x000a9; Vali-e-Asr Reproductive Health Research Center, Tehran University of Medical Sciences</copyright-statement><license><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">http://creativecommons.org/licenses/by/3.0/</ext-link>) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>
<bold>Objective:</bold> To evaluate the impact of luteal phase support with vaginal progesterone on pregnancy rates in the intrauterine insemination (IUI) cycles, stimulated with clomiphene citrate and human menopausal gonadotropin (hMG), in sub fertile couples. </p><p>
<bold>Materials and methods:</bold> This prospective, randomized, double blind study was performed in a tertiary infertility center from March 2011 to January 2012. It consisted of 253 sub fertile couples undergoing ovarian stimulation for IUI cycles. They underwent ovarian stimulation with clomiphene citrate (100 mg) and hMG (75 IU) in preparation for the IUI cycle. Study group (n = 127) received luteal phase support in the form of vaginal progesterone (400 mg twice a day), and control group (n = 126) received placebo. Clinical pregnancy and abortion rates were assessed and compared between the two groups.</p><p>
<bold>Results:</bold> The clinical pregnancy rate was not significantly higher for supported cycles than that for the unsupported ones (15.75% vs. 12.69%, p = 0.3). The abortion rate in the patients with progesterone luteal support compared to placebo group was not statistically different (10% vs. 18.75%, p = 0.45).</p><p>
<bold>Conclusion:</bold> It seems that luteal phase support with vaginal progesterone was not enhanced the success of IUI cycles outcomes, when clomiphene citrate and hMG were used for ovulation stimulation.</p></abstract><kwd-group><title>Key Words</title><kwd>clomiphene citrate</kwd><kwd>hMG</kwd><kwd>IUI</kwd><kwd>luteal phase support</kwd><kwd>progesterone</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Intrauterine insemination (IUI) is amongst the most recommended procedures to enhance the probability of pregnancy in couples with sub fertility. The success rate of this technique depends on numerous factors, one of which is the quality of the luteal phase (<xref rid="B1" ref-type="bibr">1</xref>). Luteal phase deficiency (LPD) may be associated with insufficient production of progesterone, which is essential for embryo implantation and maintenance of early pregnancy (<xref rid="B2" ref-type="bibr">2</xref>). </p><p>Clinical conditions such as stress, polycystic ovary syndrome (PCOS), aging, ovulation stimulation, ovulation induction with or without gonadotropin releasing hormone (GnRH) agonists, and assistant reproductive technologies (ART) may manifest as a LPD status (<xref rid="B3" ref-type="bibr">3</xref>-<xref rid="B9" ref-type="bibr">9</xref>). </p><p>Controlled ovarian hyper stimulation also results in multifollicular development with higher steroid serum concentrations, compared with natural cycles. It is assumed that supraphysiologic serum steroid concentrations might adversely affect LH secretion via feedback mechanisms, which in turn results in premature luteolysis and defective progesterone secretion (<xref rid="B10" ref-type="bibr">10</xref>).</p><p>Support of the luteal phase with vaginal or intramuscular progesterone is the only recognized treatment in order to escalate the clinical outcomes of stimulated IVF/intracytoplasmic sperm injection (ICSI) cycles. However, questions about the necessity of luteal support in stimulated IUI cycles remain unanswered (<xref rid="B11" ref-type="bibr">11</xref>-<xref rid="B14" ref-type="bibr">14</xref>). Unlike IVF/ICSI cycles, GnRH agonist is not administered, follicles are not aspirated, and only two or three corpus luteum are produced after ovulation stimulation in the IUI cycles. Hence, luteal phase support may not be necessary in IUI cycles (<xref rid="B15" ref-type="bibr">15</xref>).</p><p>In a systematic review and meta-analysis by Hill MJ et.al in 2013, they concluded that luteal phase support may be of benefit to patients undergoing ovulation induction with gonadotropins but not clomiphene citrate in IUI cycles (<xref rid="B16" ref-type="bibr">16</xref>).</p><p>The aim of this study was to evaluate the impact of luteal phase support on IUI cycle outcomes stimulated with clomiphene plus hMG in sub fertile couples.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><p>This prospective, randomized, double blind study was performed in a tertiary infertility center from January 2012 to December 2012. It consisted of 253 sub fertile couples undergoing ovarian stimulation for IUI cycles. Inclusion criteria were: age 20-35 years, normal hormonal assay, normal pelvis in transvaginal sonography, duration of infertility &#x02264; 5 years, and bilateral tubal patency at hystrosalpingography. Exclusion criteria were: Basal levels of FSH&#x02265;10mlU/ml, endometriosis stage 3, 4, or a history of pelvic surgery and severe male factor infertility. The patients were randomly divided into A or B groups based on a computer generated list, while neither the patients nor the procedure developer had any information about the treatment assignment. Before the project commenced, the study was approved by the University Ethics Committee.</p><p>In all patients a transvaginal ultrasonography (TVS) was performed on the third day of their menstrual cycle, and 100 mg of clomiphene citrate oral tablet (Iran Hormone Co., Tehran, Iran) was administered if both ovaries appeared normal from day 3 of menstrual cycle for 5 days. Furthermore, from the day 7 of cycle 75 IU of hMG (Menopur, Ferring SAS, Switzerland) was injected intramuscularly for a period of at least three days depending on ovarian response. Patients were re-evaluated by TVS to assess the ovarian response on the tenth day. TVS was performed every two to three days if necessary until at least one follicle &#x02265; 18mm was seen. In that case, 10 000 IU of human chorionic gonadotropin (Pregnyl, 5000IU, MSD,Greek) was injected intramuscularly. However, if more than three dominant follicles were seen, the cycle would have been cancelled to prevent ovarian hyper stimulation syndrome (OHSS).</p><p>Semen preparation was performed using the standard swim up technique in the same lab. Then IUI was done once by IUI catheter (Rocket Medical, Watford, UK) attached to a 1-ml syringe, 36 hours after HCG administration. The study group (A, n=127) received luteal phase support in the form of vaginal progesterone, (400 mg twice a day), while the control group (B, n=126) received a placebo, which both started two days after the administration of hCG, and this was continued until a pregnancy test was performed. Both drugs were made by the Aburaihan Pharmaceutical Company, Tehran, Iran and were similar in appearance. The luteal phase support was continued in the two groups until the eighth week, if the pregnancy test was positive. </p><p>The data were analyzed by SPSS software version 20 (Statistical Product and Service Solutions, SPSS Inc., Chicago), chi-square, and T test, while p&#x02264;0.05 was regarded statistically significant. Results are presented as mean &#x000b1; SD and percentages.</p></sec><sec sec-type="results"><title>Results</title><p>In total, 253 women went through ovarian stimulation with clomiphene citrate (100 mg) and hMG (75 IU) for an IUI cycle. There were 127 women in the progesterone group and 126 in the placebo group. Demographic characteristics of the patients in the two groups are reported in <xref ref-type="table" rid="T1">Table 1</xref>.</p><p>Two groups were comparable regarding age, BMI, cause of infertility, and the duration of infertility.</p><p>We also compared the basal FSH and LH levels, the number of dominant follicules&#x02265;18mm and the serum progesterone on HCG day between progesterone and placebo groups. There was no statistically significant difference regarding thesevariables.</p><p>Treatment outcomes depicted in <xref ref-type="table" rid="T2">Table 2</xref>. The chemical and clinical pregnancy rate was not significantly different in group receiving vaginal progesterone comparing with placebo (15.75% vs. 12.69%, respectively; P = 0.30). The abortion rate was also the same in the progesterone and placebo group (10% vs. 18.75%, respectively; P = 0.45.)</p><p>In patients older than 30 years, the pregnancy rate after luteal phase support with progesterone was significantly higher than in the younger women aged &#x02264;30 years (P = 0.018).</p></sec><sec sec-type="discussion"><title>Discussion</title><p>In this study, luteal phase support with vaginal progesterone and vaginal placebo was compared in patients undergoing ovarian stimulation with clomiphene citrate and hMG in IUI cycles.</p><p>Although the benefit of progesterone administration has been well documented in IVF (<xref rid="B15" ref-type="bibr">15</xref>), the question remains whether it is really necessary in mildly stimulated IUI cycles, in which 1-2 follicles have developed (<xref rid="B17" ref-type="bibr">17</xref>).</p><p>Erdem et al. showed that luteal phase support with progesterone increases pregnancy rates in IUI cycles stimulated with gonadotropins in patients with unexplained infertility (<xref rid="B10" ref-type="bibr">10</xref>).</p><p>These findings was in accordance with a similar study done by Agha-Hosseini et.al , who indicated for better pregnancy outcomes in unexplained infertility when supported with vaginal progesterone (<xref rid="B18" ref-type="bibr">18</xref>).</p><p>Luteal phase LH levels were found to be reduced in hMG-only cycles, which also indicate that defective LH secretion might induce a luteal phase defect in hMG stimulated cycles(<xref rid="B9" ref-type="bibr">9</xref>).</p><p>In another study, Maher described the cycle in which recombinant follicular stimulating hormones (r-FSH) were used for ovulation induction, and luteal phase support with vaginal progesterone improved the success of the IUI cycles (<xref rid="B19" ref-type="bibr">19</xref>).</p><p>On the contrary we did not find any significant difference in terms of chemical and pregnancy rates. </p><p>Kyrou et al. concluded that luteal phase supplementation with vaginal progesterone did not improve pregnancy rates in normo-ovulatory women stimulated with clomiphene citrate for IUI, but mentioned that their study was under-powered in regards to detecting the difference in the ongoing pregnancy rate (<xref rid="B17" ref-type="bibr">17</xref>).</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Demographic characteristics of patients in both groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th style="background-color:#4A6E62; color:#FFFFFF;" align="left" valign="middle" rowspan="2" colspan="1">
<bold>Variable</bold>
</th><th style="background-color:#4A6E62; color:#FFFFFF;" align="center" rowspan="1" colspan="1">
<bold>Progesterone group</bold>
<hr/>
</th><th style="background-color:#4A6E62; color:#FFFFFF;" align="center" rowspan="1" colspan="1">
<bold>Placebo group</bold>
<hr/>
</th><th style="background-color:#4A6E62; color:#FFFFFF;" align="center" valign="middle" rowspan="2" colspan="1">
<bold>p-value</bold>
</th></tr><tr><th style="background-color:#4A6E62; color:#FFFFFF;" align="center" rowspan="1" colspan="1">
<bold>(n = 127)</bold>
</th><th style="background-color:#4A6E62; color:#FFFFFF;" align="center" rowspan="1" colspan="1">
<bold>(n = 126)</bold>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (yrs.) <xref ref-type="table-fn" rid="TFN1">a</xref></td><td align="center" rowspan="1" colspan="1">27.53 &#x000b1; 4.23</td><td align="center" rowspan="1" colspan="1">28.11 &#x000b1; 4.62</td><td align="center" rowspan="1" colspan="1">0.30</td></tr><tr><td style="background-color:#E6EED5;" align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>) <xref ref-type="table-fn" rid="TFN1">a</xref></td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">22.7 &#x000b1; 2.8</td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">22.6&#x000b1; 2.6</td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">0.25</td></tr><tr><td align="left" rowspan="1" colspan="1">Duration of Infertility (yrs) <xref ref-type="table-fn" rid="TFN1">a</xref></td><td align="center" rowspan="1" colspan="1">4.55 &#x000b1; 3.35</td><td align="center" rowspan="1" colspan="1">4.71 &#x000b1; 3.34</td><td align="center" rowspan="1" colspan="1">0.70</td></tr><tr><td style="background-color:#E6EED5;" align="left" rowspan="1" colspan="1">Progesterone level on</td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">0.7 &#x000b1;0.3</td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">0.6 &#x000b1; 0.3</td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">0.65</td></tr><tr><td align="left" rowspan="1" colspan="1">hCG day (ng/ml) <xref ref-type="table-fn" rid="TFN1">a</xref></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td style="background-color:#E6EED5;" align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Basal level of FSH (mIu/ml) <xref ref-type="table-fn" rid="TFN1">a</xref></td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">5.98 &#x000b1; 2.33</td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">6.38 &#x000b1; 2.56</td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">0.19</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Basal level of LH (mIu/ml) <xref ref-type="table-fn" rid="TFN1">a</xref></td><td align="center" rowspan="1" colspan="1">8.15 &#x000b1; 5.90</td><td align="center" rowspan="1" colspan="1">8.28 &#x000b1; 2.96</td><td align="center" rowspan="1" colspan="1">0.82</td></tr><tr><td style="background-color:#E6EED5;" align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;No of Dominant follicles<xref ref-type="table-fn" rid="TFN1">a</xref></td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">2.21 &#x000b1; 1.29</td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">2.43 &#x000b1; 1.31</td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">0.18</td></tr><tr><td align="left" rowspan="1" colspan="1">Cause n (%)<xref ref-type="table-fn" rid="TFN2">b</xref></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td style="background-color:#E6EED5;" align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Unexplained</td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">33 (26)</td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">31 (25)</td><td align="center" valign="middle" rowspan="3" colspan="1">0.93</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;anovulatory</td><td align="center" rowspan="1" colspan="1">69 (54)</td><td align="center" rowspan="1" colspan="1">68 (54)</td></tr><tr><td style="background-color:#E6EED5;" align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Male</td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">25 (20)</td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">27 (21)</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><label>a</label><p> Values are reported as mean &#x000b1; SD and were analyzed by student's test;</p></fn><fn id="TFN2"><label>b</label><p> Values were analyzed by &#x003c7;2 test</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Treatment Outcomes</p></caption><table frame="hsides" rules="groups"><thead><tr><th style="background-color:#4A6E62; color:#FFFFFF;" align="left" valign="middle" rowspan="2" colspan="1">
<bold>Variable</bold>
</th><th style="background-color:#4A6E62; color:#FFFFFF;" align="center" rowspan="1" colspan="1">
<bold>Progesterone group</bold>
<hr/>
</th><th style="background-color:#4A6E62; color:#FFFFFF;" align="center" rowspan="1" colspan="1">
<bold>Placebo group</bold>
<hr/>
</th><th style="background-color:#4A6E62; color:#FFFFFF;" align="center" valign="middle" rowspan="2" colspan="1">
<bold>p-value</bold>
</th></tr><tr><th style="background-color:#4A6E62; color:#FFFFFF;" align="center" rowspan="1" colspan="1">
<bold>(n = 127)</bold>
</th><th style="background-color:#4A6E62; color:#FFFFFF;" align="center" rowspan="1" colspan="1">
<bold>(n = 126)</bold>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Chemical Pregnancy rate<sup>b</sup><break/>n (%)</td><td align="center" rowspan="1" colspan="1">39 (30.76)</td><td align="center" rowspan="1" colspan="1">28 (22.22)</td><td align="center" rowspan="1" colspan="1">0.15</td></tr><tr><td style="background-color:#E6EED5;" align="left" rowspan="1" colspan="1">Clinical Pregnancy rate<sup>b</sup><break/>n (%)</td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">20 (15.75%)</td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">16 (12.69%)</td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">0.30</td></tr><tr><td align="left" rowspan="1" colspan="1">Abortion rate<sup>b</sup><break/>n (%)</td><td align="center" rowspan="1" colspan="1">2 (10)</td><td align="center" rowspan="1" colspan="1">3 (18.75)</td><td align="center" rowspan="1" colspan="1">0.45</td></tr><tr><td style="background-color:#E6EED5;" align="left" rowspan="1" colspan="1">Ongoing pregnancy rate<sup>b</sup><break/>n (%)</td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">18 (46.2)</td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">13 (46.4)</td><td style="background-color:#E6EED5;" align="center" rowspan="1" colspan="1">0.98</td></tr></tbody></table><table-wrap-foot><p>Values were analyzed by &#x003c7;2 test; p &#x002c2; 0.05 was considered statistically significant</p></table-wrap-foot></table-wrap><p>It is worth to emphasize that all of the above mentioned study compared supported cycles with unsupported luteal phase. While, we take into consideration the placebo effect by using placebo in control group, which is the strength of our study. </p><p>On the other hand, it was shown that LH secretions are reduced to almost undetectable levels shortly after the ovulatory hCG injection, and remain low for the whole length of the luteal phase, which indicates that defective LH secretion might induce a luteal phase defect in stimulated cycles (<xref rid="B10" ref-type="bibr">10</xref>), so it was reasonable for us using progesterone in our study, for luteal phase support irrespective of the type of stimulatory drug (clomiphene or hMG or both).</p><p>However, Montville et al. came to the conclusion that luteal phase support with progesterone in women suffering from PCOS stimulated with letrozole improved clinical pregnancy rates, although the results were on the contrary for women stimulated with clomiphene citrate (<xref rid="B20" ref-type="bibr">20</xref>).</p><p>Ragni et al. compared the luteal phase profile in patients stimulated with gonadotropin and GnRH antagonist for IUI cycles, with those without the GnRH antagonist. They demonstrated that the progesterone level was similar in the luteal phase in both groups. Considering this fact, they suggested that the GnRH antagonist is a safe procedure in gonadotropin stimulated IUI cycles without luteal phase supplementation (<xref rid="B21" ref-type="bibr">21</xref>). But, they used gonadotropin for induction of ovulation and not clomiphene citrate followed by gonadotropin as we used in our study.</p><p>A systematic review and meta-analysis in 2013 was performed by Hill MJ et.al which included five trials comprised 1298 patients. They concluded that luteal phase support may be of benefit to patients undergoing ovulation induction with gonadotropins but not clomiphene citrate in IUI cycles, suggesting a potential difference in endogenous luteal phase function depending on the method of ovulation induction (<xref rid="B16" ref-type="bibr">16</xref>).</p><p>The finding of this systematic review supported the results of Tavaniotou et al study (<xref rid="B9" ref-type="bibr">9</xref>).</p><p>Comparing the results of progesterone administration in women under the age 30, to women more than 30, showed the trend toward higher pregnancy rates which supported the previous hypothesis and studies (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B22" ref-type="bibr">22</xref>).</p><p>With regard to the previous studies about this subject the design of our study was different in three important points. First, it was comprised of all kinds of sub fertile patients who were suitable for IUI cycle. The second difference was the use of placebo in the control group. And at last, ovarian stimulation was performed by using clomiphene and gonadotropin together.</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>Luteal phase support may be more beneficial in older women in IUI cycles. Moreover, regarding to our study design, using clomiphene in association with gonadotropin for induction ovulation in patients who undergoing IUI cycle, may result better in terms of luteal phase function and pregnancy outcomes. </p></sec></body><back><ack><title>Acknowledgments</title><p>The authors would like to thank Miss Bagheri and Mrs. Masumi for collecting the patients&#x02019; data. We had no conflicts of interest.</p></ack><sec><title>Confilict of Interests</title><p>Authors declare that they have no conflict of interest.</p></sec><ref-list><title>References</title><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohlen</surname><given-names>BJ</given-names></name></person-group><article-title>Should luteal phase support be introduced in ovarian stimulation/IUI programmes? An evidence-based review</article-title><source> Reprod Biomed Online</source><year>2009</year><volume>19</volume><issue>Suppl. 4</issue><fpage>31</fpage><lpage>8</lpage></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cspo</surname><given-names>AL</given-names></name><name><surname>Pulkkinen</surname><given-names>MO</given-names></name><name><surname>Ruttner</surname><given-names>B</given-names></name><name><surname>Sauvage</surname><given-names>JP</given-names></name></person-group><article-title>Wiest WG</article-title><source> The significance of the human corpus luteum in pregnancy maintenance. Preliminary studies .Am J Obstet Gynecol</source><year>1972</year><volume>112</volume><fpage>1061</fpage><lpage>7</lpage></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><collab>American Society for Reproductive Medicine</collab><article-title>The clinical relevance of luteal phase deficiency: a committee opinion</article-title><source> Fertili and Sterili</source><year>2012</year><volume>98</volume><fpage>1112</fpage><lpage>7</lpage></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kajantie</surname><given-names>E</given-names></name><name><surname>Phillips</surname><given-names>DI</given-names></name></person-group><article-title>The effects of sex and hormonal status on the physiological response to acute psychosocial stress</article-title><source> Psychoneuroendocrinol</source><year>2006</year><volume>31</volume><fpage>151</fpage><lpage>78</lpage></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>E</given-names></name><name><surname>Xia-Zhang</surname><given-names>L</given-names></name><name><surname>Ferin</surname><given-names>M</given-names></name></person-group><article-title>Inadequate luteal function is the initial clinical cyclic deficiency in a 12-day stress model that includes a psychogenic component in the Rhesus monkey</article-title><source> J Clin Endcrinol Metab </source><year>2002</year><volume>87</volume><fpage>2232</fpage><lpage>7</lpage></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Filicari</surname><given-names>M</given-names></name><name><surname>Flamigni</surname><given-names>C</given-names></name><name><surname>Meriggida</surname><given-names>MC</given-names></name><name><surname>Ferrari</surname><given-names>P</given-names></name><name><surname>Michelacci</surname><given-names>L</given-names></name><etal/></person-group><article-title>Endocrine response determines the clinical outcome of pulsatile gonadotropin releasing hormone ovulation induction in different ovulatory disorders</article-title><source> J Clin Endcrinol Metab</source><year>1991</year><volume>72</volume><fpage>965</fpage><lpage>72</lpage></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prior</surname><given-names>JC</given-names></name></person-group><article-title>Ovarian aging and the perimenopausal transition: the paradox of endogenous ovarian hyper stimulation</article-title><source> Endocrine</source><year>2005</year><volume>26</volume><fpage>297</fpage><lpage>300</lpage><pub-id pub-id-type="pmid">16034185</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olson</surname><given-names>JL</given-names></name><name><surname>Rebar</surname><given-names>RW</given-names></name><name><surname>Schreiber</surname><given-names>JR</given-names></name><name><surname>vaitukaltis</surname><given-names>JL</given-names></name></person-group><article-title>Shortened luteal phase after ovulation induction with human menopausal gonadotropin and human chorionic gonadotropin</article-title><source> Fertil steril</source><year>1983</year><volume>39</volume><fpage>284</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">6402386</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tavaniotou</surname><given-names>A</given-names></name><name><surname>Allbano</surname><given-names>C</given-names></name><name><surname>Smitz</surname><given-names>J</given-names></name><name><surname>Devroey</surname><given-names>P</given-names></name></person-group><article-title>Impact of ovarian stimulation on corpus luteum function and embryonic implantation</article-title><source> J Reprod Immunol</source><year>2002</year><volume>55</volume><fpage>123</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">12062827</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erdem</surname><given-names>A</given-names></name><name><surname>Erdem</surname><given-names>M</given-names></name><name><surname>Atmaca</surname><given-names>S</given-names></name><name><surname>Guler</surname><given-names>I</given-names></name></person-group><article-title>Impact of luteal phase support on pregnancy rates in intrauterine insemination cycles: a prospective randomized study</article-title><source> Fertil Steril</source><year>2009</year><volume>91</volume><fpage>2508</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">18692788</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van</surname><given-names>der Linden M</given-names></name><name><surname>Buckingham</surname><given-names>K</given-names></name><name><surname>Farquhar</surname><given-names>C</given-names></name><name><surname>Kermer</surname><given-names>JAM</given-names></name><name><surname>Mitwally</surname><given-names>M</given-names></name></person-group><article-title>Luteal phase support for assisted reproduction cycles (Review)</article-title><source>The Cochrane Collaboration</source><year>2012</year></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pritts</surname><given-names>EA</given-names></name><name><surname>Atwood</surname><given-names>AK</given-names></name></person-group><article-title>Luteal phase support in infertility treatment: a meta-analysis of the randomized trials</article-title><source> Hum Reprod</source><year>2002</year><volume>17</volume><fpage>2287</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">12202415</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daya</surname><given-names>S</given-names></name><name><surname>Gunby</surname><given-names>J</given-names></name></person-group><article-title>Luteal phase support in assisted reproduction cycles</article-title><source> Cochrane Database Systematic Reviews</source><year>2004</year><volume>3</volume><fpage>CD004830</fpage></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><collab>Practice Committee of the American Society for reproductive Medicine</collab><article-title>Progesterone supplementation during the luteal phase and in early pregnancy in the treatment of infertility: an education bulletin</article-title><source> Fertil Steril</source><year>2008</year><volume>89</volume><fpage>789</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">18406835</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fatemi</surname><given-names>HM</given-names></name><name><surname>Popovic-</surname><given-names>Todorovic B</given-names></name><name><surname>Papanikolaou</surname><given-names>E</given-names></name><name><surname>Donoso</surname><given-names>P</given-names></name><name><surname>Dervroey</surname><given-names>P</given-names></name></person-group><article-title>An update of luteal phase support in stimulated IVF cycles</article-title><source> Hum Reprod Update</source><year>2007</year><volume>13</volume><fpage>581</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">17626114</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>MJ</given-names></name><name><surname>Whitcomb</surname><given-names>BW</given-names></name><name><surname>Lewis</surname><given-names>TD</given-names></name><name><surname>Wu</surname><given-names>M</given-names></name><name><surname>Terry</surname><given-names>N</given-names></name><name><surname>et.al</surname><given-names/></name></person-group><article-title> Progesterone luteal support after ovulation induction and intrauterine insemination: a systematic review and meta-analysis.</article-title><source>Fertil Steril</source><year>2013</year><volume>100</volume><fpage>1373</fpage><lpage>1380</lpage><pub-id pub-id-type="pmid">23876537</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kyrou</surname><given-names>D</given-names></name><name><surname>Fatemi</surname><given-names>H M</given-names></name><name><surname>Tournaye</surname><given-names>H</given-names></name><name><surname>Devroey</surname><given-names>P</given-names></name></person-group><article-title>Luteal phase support in normo-ovulatory women stimulated with clomiphene citrate for intrauterine insemination: need or habit? </article-title><source>Hum reproduce</source><year>2010</year><volume>25</volume><fpage>2501</fpage><lpage>06</lpage></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agha-Hosseini</surname><given-names>M</given-names></name><name><surname>Rahmani</surname><given-names>M</given-names></name><name><surname>Alleyasin</surname><given-names>A</given-names></name><name><surname>Safdariyan</surname><given-names>L</given-names></name><name><surname>Sarvi</surname><given-names>F</given-names></name></person-group><article-title>The effect of progesterone on pregnancy rates in controlled ovarian stimulation and intrauterine insemination cycles: a randomized prospective trial</article-title><source> Eur J Obstet Gynecol Reprod Biol</source><year>2012</year><volume>165</volume><fpage>249</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">22940119</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maher</surname><given-names>MA</given-names></name></person-group><article-title>Luteal phase support may improve pregnancy outcomes during intrauterine insemination cycles</article-title><source> Eur J Obstet Gynecol Reprod Biol</source><year>2011</year><volume>157</volume><fpage>57</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">21514032</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montville</surname><given-names>C</given-names></name><name><surname>Khabbaz</surname><given-names>M</given-names></name><name><surname>Aubuchon</surname><given-names>M</given-names></name><name><surname>Williams</surname><given-names>D</given-names></name><name><surname>Thomas</surname><given-names>M</given-names></name></person-group><article-title>Luteal support with intravaginal progesterone increases clinical pregnancy rates in women with polycystic ovary syndrome using letrozole for ovulation induction</article-title><source> Fertil Steril</source><year>2010</year><volume>94</volume><fpage>678</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">19515366</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ragni</surname><given-names>G</given-names></name><name><surname>Vegetti</surname><given-names>W</given-names></name><name><surname>Baroni</surname><given-names>E</given-names></name><name><surname>Colombo</surname><given-names>M</given-names></name><name><surname>Arnoldi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Comparison of luteal phase profile in gonadotrophin stimulated cycles with or without a gonadotrophin-releasing hormone antagonist</article-title><source> Hum Reprod</source><year>2001</year><volume>16</volume><fpage>2258</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">11679500</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mersereau</surname><given-names>JE</given-names></name><name><surname>Evans</surname><given-names>ML</given-names></name><name><surname>Moore</surname><given-names>DH</given-names></name><name><surname>Liu</surname><given-names>JH</given-names></name><name><surname>Thomas</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Luteal phase estrogen is decreased in regularly menstruating older women compared with a reference population of younger women</article-title><source> Menopause</source><year>2008</year><volume>15</volume><fpage>482</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">18202592</pub-id></element-citation></ref></ref-list></back></article>